Duchenne drug fails in rare confirmatory trial

Japanese drugmaker Nippon Shinyaku said that Viltepso had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

May 27, 2024 Check out STAT+

Sponsored By

Dr. Edwin P. Ewing, Jr./CDC STAT+ | Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of Duchenne drugs. By Jason Mast STAT+ | ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care From the 5,000 abstracts being published at the ASCO cancer meeting, STAT spotted those that look impactful, innovative, and interesting. By Angus Chen Opinion: The world needs the new pandemic treaty Global health security depends on WHO member nations ratifying and adhering to an agreement that will bring equity to pandemic preparedness. By Alexandra Phelan and Lawrence O. Gostin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser